Haemonetics (HAE) Tops Q3 EPS by 2c; updates guidance

Haemonetics (NYSE: HAE) reported Q3 EPS of $1.19, $0.02 better than the analyst estimate of $1.17. Revenue for the quarter came in at $349 million versus the consensus estimate of $352.98 million.

GUIDANCE:

Haemonetics sees FY2025 EPS of $4.50-$4.70, versus the consensus of $4.59.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
• Bernstein SocGen on Oracle (ORCL): 'Next catalyst is FAM'
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance